Stock Financial Ratios, Dividends, Split History

HTS / Hatteras Financial Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price16.27
Volume1,524,000.00
Market Cap ($M)1,537.99
Book Value ($M)2,045.37
Book Value / Share21.64
Price / Book0.75
NCAV / Share-144.77
Price / NCAVn/a
Share Statistics
Preferred Stock Shares Outstanding 11,500,000
Weighted Average Number Of Diluted Shares Outstanding 96,665,489
Weighted Average Number Of Shares Outstanding Basic 96,665,489
Common Stock Shares Outstanding 95,773,767
Common Shares Outstanding 94,533,206
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.00
Return on Assets (ROA)0.00
Return on Equity (ROE)0.02
Balance Sheet (mrq) ($M)
Assets14,094.50
Liabilities12,049.13
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Net Income51.62
Cash Flow Statement (mra) ($M)
Cash From Operations338.23
Cash from Investing2,270.48
Cash from Financing338.23
Identifiers and Descriptors
CUSIP41902R103
Central Index Key (CIK)1419521
Related CUSIPS
41STKR992 41902R953 41902R903

Split History

Stock splits are used by Hatteras Financial Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

AGNC Investment's Q2 2018 And 7/13/2018 BV Projection (Includes NLY BV Projection)

2018-07-18 seekingalpha
I am projecting AGNC will report a minor decrease in quarterly BV for the second quarter of 2018. Most agency peers will also experience a similar type of BV decrease. (13-0)

AGNC Investment's Q2 2018 Income Statement And Earnings Preview - Part 3 (Modest MBS Price Decreases)

2018-07-16 seekingalpha
I am projecting AGNC will report a combined modest-notable net unrealized loss on available-for-sale securities and investment securities measured at FMV for the second quarter of 2018. (29-0)

American Superconductor: Where To Now?

2018-07-11 seekingalpha
The Sinovel settlement of $58M is disappointing, but the commercial prospects of the grid segment remain unchanged.

AGNC Investment's Q2 2018 Income Statement And Earnings Preview - Part 1 (Including Current Recommendation)

2018-07-02 seekingalpha
This series projects AGNC’s income statement for the second quarter of 2018. These projections help readers understand how most of the fixed-rate agency mREIT sector performed. (51-1)

AGNC Investment's Q1 2018 And 4/17/2018 BV Projection (Includes MTGE And NLY BV Projection)

2018-04-18 seekingalpha
I am projecting AGNC will report a modest decrease in quarterly BV for the first quarter of 2018. Most sector peers will also experience a BV decrease (especially fixed-rate agency). (54-0)

CUSIP: 41902R103